Cargando…
Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells
Liver iron excess is observed in several chronic liver diseases and is associated with the development of hepatocellular carcinoma (HCC). However, apart from oxidative stress, other cellular mechanisms by which excess iron may mediate/increase HCC predisposition/progression are not known. HCC pathol...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736862/ https://www.ncbi.nlm.nih.gov/pubmed/33318518 http://dx.doi.org/10.1038/s41598-020-78348-5 |
_version_ | 1783622853953847296 |
---|---|
author | Mehta, Kosha J. Sharp, Paul A. |
author_facet | Mehta, Kosha J. Sharp, Paul A. |
author_sort | Mehta, Kosha J. |
collection | PubMed |
description | Liver iron excess is observed in several chronic liver diseases and is associated with the development of hepatocellular carcinoma (HCC). However, apart from oxidative stress, other cellular mechanisms by which excess iron may mediate/increase HCC predisposition/progression are not known. HCC pathology involves epithelial to mesenchymal transition (EMT), the basis of cancer phenotype acquisition. Here, the effect of excess iron (holo-transferrin 0–2 g/L for 24 and 48 h) on EMT biomarkers in the liver-derived HepG2 cells was investigated. Holo-transferrin substantially increased intracellular iron. Unexpectedly, mRNA and protein expression of the epithelial marker E-cadherin either remained unaltered or increased. The mRNA and protein levels of metastasis marker N-cadherin and mesenchymal marker vimentin increased significantly. While the mRNA expression of EMT transcription factors SNAI1 and SNAI2 increased and decreased, respectively after 24 h, both factors increased after 48 h. The mRNA expression of TGF-β (EMT-inducer) showed no significant alterations. In conclusion, data showed direct link between iron and EMT. Iron elevated mesenchymal and metastatic biomarkers in HepG2 cells without concomitant decrement in the epithelial marker E-cadherin and altered the expression of the key EMT-mediating transcription factors. Such studies can help identify molecular targets to devise iron-related adjunctive therapies to ameliorate HCC pathophysiology. |
format | Online Article Text |
id | pubmed-7736862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-77368622020-12-15 Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells Mehta, Kosha J. Sharp, Paul A. Sci Rep Article Liver iron excess is observed in several chronic liver diseases and is associated with the development of hepatocellular carcinoma (HCC). However, apart from oxidative stress, other cellular mechanisms by which excess iron may mediate/increase HCC predisposition/progression are not known. HCC pathology involves epithelial to mesenchymal transition (EMT), the basis of cancer phenotype acquisition. Here, the effect of excess iron (holo-transferrin 0–2 g/L for 24 and 48 h) on EMT biomarkers in the liver-derived HepG2 cells was investigated. Holo-transferrin substantially increased intracellular iron. Unexpectedly, mRNA and protein expression of the epithelial marker E-cadherin either remained unaltered or increased. The mRNA and protein levels of metastasis marker N-cadherin and mesenchymal marker vimentin increased significantly. While the mRNA expression of EMT transcription factors SNAI1 and SNAI2 increased and decreased, respectively after 24 h, both factors increased after 48 h. The mRNA expression of TGF-β (EMT-inducer) showed no significant alterations. In conclusion, data showed direct link between iron and EMT. Iron elevated mesenchymal and metastatic biomarkers in HepG2 cells without concomitant decrement in the epithelial marker E-cadherin and altered the expression of the key EMT-mediating transcription factors. Such studies can help identify molecular targets to devise iron-related adjunctive therapies to ameliorate HCC pathophysiology. Nature Publishing Group UK 2020-12-14 /pmc/articles/PMC7736862/ /pubmed/33318518 http://dx.doi.org/10.1038/s41598-020-78348-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Mehta, Kosha J. Sharp, Paul A. Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells |
title | Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells |
title_full | Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells |
title_fullStr | Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells |
title_full_unstemmed | Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells |
title_short | Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells |
title_sort | iron elevates mesenchymal and metastatic biomarkers in hepg2 cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736862/ https://www.ncbi.nlm.nih.gov/pubmed/33318518 http://dx.doi.org/10.1038/s41598-020-78348-5 |
work_keys_str_mv | AT mehtakoshaj ironelevatesmesenchymalandmetastaticbiomarkersinhepg2cells AT sharppaula ironelevatesmesenchymalandmetastaticbiomarkersinhepg2cells |